SYD 985

Drug Profile

SYD 985

Alternative Names: Anti-HER2 ADC SYD985; SYD985; Trastuzumab vc-seco-DUBA

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Synthon
  • Class Antineoplastics; Bacterial toxins; Cytostatic antibiotics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small molecules
  • Mechanism of Action Alkylating agents; DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer; Solid tumours
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in Netherlands (IV, Infusion)
  • 01 May 2016 Synthon announces intention to submit a pre-IND meeting request to the US FDA
  • 25 Nov 2014 Phase-I clinical trials in Solid tumours, including Breast cancer and Gastric cancer (Late-stage disease, Second-line therapy or greater) in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top